Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Topline Data Support Self-Administered Nasal Spray for Heart Arrythmia

  • Post author:PacConAdmin
  • Post published:October 17, 2022
  • Post category:Drug Industry Daily

Milestone Pharmaceuticals’ investigational nasal spray etripamil claimed a phase 3 win, with topline data indicating that abnormal heart rhythms normalized in 64 percent of patients with paroxysmal supraventricular tachycardia (PSVT)…

Continue ReadingTopline Data Support Self-Administered Nasal Spray for Heart Arrythmia

FDA Issues Trio of Oncology Drug Development Guidances

  • Post author:PacConAdmin
  • Post published:October 17, 2022
  • Post category:Drug Industry Daily

In a trio of guidances released Monday, the FDA laid out new recommendations for research on cancer drugs, including how to develop drugs for acute myeloid leukemia (AML), how to…

Continue ReadingFDA Issues Trio of Oncology Drug Development Guidances

Covis, FDA Go Head-to-Head Over Makena Marketing Withdrawal

  • Post author:PacConAdmin
  • Post published:October 17, 2022
  • Post category:Drug Industry Daily

A failure to withdraw marketing approval of Covis’ preterm birth drug Makena would amount to a failure of FDA’s Accelerated Approval pathway, according to Peter Stein, director of the agency’s…

Continue ReadingCovis, FDA Go Head-to-Head Over Makena Marketing Withdrawal

DOJ Pursues Alleged Trial Data Falsification at Miami Site

  • Post author:PacConAdmin
  • Post published:October 16, 2022
  • Post category:Drug Industry Daily

The U.S. Department of Justice (DOJ) announced that three members of a Miami-based research center have been charged for allegedly running a years-long scheme to falsify clinical trial data for…

Continue ReadingDOJ Pursues Alleged Trial Data Falsification at Miami Site

HHS/CMS to Develop Plan for Lowering Prescription Drug Costs Through Medicare

  • Post author:PacConAdmin
  • Post published:October 16, 2022
  • Post category:Drug Industry Daily

The Department of Health and Human Services (HHS) will have to come up with a plan to force down the cost of prescription drugs under an executive order signed by…

Continue ReadingHHS/CMS to Develop Plan for Lowering Prescription Drug Costs Through Medicare

FDA Offers Revised Guidance on Prior Approval Supplements Under GDUFA III

  • Post author:PacConAdmin
  • Post published:October 16, 2022
  • Post category:Drug Industry Daily

In the wake of the reauthorization of the Generic Drug User Fee Amendments (GDUFA), the FDA has updated its guidance for prior approval supplements (PAS) and amendments for abbreviated new…

Continue ReadingFDA Offers Revised Guidance on Prior Approval Supplements Under GDUFA III

Fresenius Kabi’s Illinois Plant Draws Form 483 for Batch Discrepancies, Contamination

  • Post author:PacConAdmin
  • Post published:October 14, 2022
  • Post category:Drug Industry Daily

The FDA rapped Fresenius Kabi for batch discrepancies and contamination issues, among other quality lapses, following an inspection of its Melrose Park, Ill., facility. Source: Drug Industry Daily

Continue ReadingFresenius Kabi’s Illinois Plant Draws Form 483 for Batch Discrepancies, Contamination

Fate of FDA Orphan Drug Exclusivity Still in the Balance, Agency Official Says

  • Post author:PacConAdmin
  • Post published:October 13, 2022
  • Post category:Drug Industry Daily

After years of legal wrangling, the FDA is still grappling with the issue of how exactly to define “exclusivity” in its orphan drug program, according to one senior agency official…

Continue ReadingFate of FDA Orphan Drug Exclusivity Still in the Balance, Agency Official Says

GSK’s RSV Vaccine Highly Effective Against Severe Disease in Older Adults, Data Show

  • Post author:PacConAdmin
  • Post published:October 13, 2022
  • Post category:Drug Industry Daily

GSK has unveiled impressive numbers for its respiratory syncytial virus (RSV) vaccine, touting an overall efficacy rate of more than 94 percent against severe disease in people age 60 years…

Continue ReadingGSK’s RSV Vaccine Highly Effective Against Severe Disease in Older Adults, Data Show

FDA Offers Advice on CMC Postapproval Changes

  • Post author:PacConAdmin
  • Post published:October 13, 2022
  • Post category:Drug Industry Daily

Companies submitting or holding drug applications who plan to implement a chemistry, manufacturing, and controls (CMC) postapproval change may gain faster agency reviews using a comparability protocol (CP), according to…

Continue ReadingFDA Offers Advice on CMC Postapproval Changes
  • Go to the previous page
  • 1
  • …
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.